No Data
Cytokinetics to Participate in December Investor Conferences
JMP Securities Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $78
Optimistic Outlook for Cytokinetics Amidst Promising Aficamten Developments and Regulatory Progress
Needham Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $72
Cytokinetics Price Target Maintained With a $72.00/Share by Needham
Cytokinetics Analyst Ratings